Parkwood LLC Tg Therapeutics, Inc. Transaction History

Parkwood LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$13.32 - $19.19 $1.75 Million - $2.53 Million	131,609 Added 818.92%	147,680 $9.85 Million
Q1 2024 May 15, 2024	SELL	$13.02 - $21.3 $107,753 - $176,278	-8,276 Reduced 33.99%	16,071 $8.63 Million
Q4 2023 Feb 14, 2024	SELL	$6.68 - $18.81 $942,327 - $2.65 Million	-141,067 Reduced 85.28%	24,347 $1.88 Million
Q3 2023 Nov 14, 2023	BUY	$8.36 - $26.5 $1.38 Million - $4.38 Million	165,414 New	165,414 $6.08 Million
Q1 2023 May 15, 2023	SELL	$10.23 - $19.34 $55,661 - $105,228	-5,441 Reduced 20.26%	21,415 $531,000
Q4 2022 Feb 14, 2023	SELL	$5.01 - $11.83 $7.23 Million - $17.1 Million	-1,442,427 Reduced 98.17%	26,856 $5.5 Million
Q3 2022 Nov 14, 2022	BUY	$4.57 - $8.4 $6.5 Million - $11.9 Million	1,422,115 Added 3015.0%	1,469,283 $10.7 Million
Q2 2022 Aug 15, 2022	SELL	$3.74 - $10.66 $10,314 - $29,400	-2,758 Reduced 5.52%	47,168 $47,000
Q1 2022 May 13, 2022	BUY	$7.81 - $20.45 $362,430 - $949,002	46,406 Added 1318.35%	49,926 $4.69 Million
Q4 2021 Feb 11, 2022	SELL	$15.2 - $35.51 $559,375 - $1.31 Million	-36,801 Reduced 91.27%	3,520 $4.85 Million
Q3 2021 Nov 12, 2021	BUY	$21.78 - $40.45 $291,808 - $541,949	13,398 Added 49.76%	40,321 $5.15 Million
Q2 2021 Aug 13, 2021	SELL	$32.5 - $48.96 $164,190 - $247,345	-5,052 Reduced 15.8%	26,923 $1.89 Million
Q1 2021 May 14, 2021	BUY	$41.61 - $54.3 $20,888 - $27,258	502 Added 1.6%	31,975 $1.54 Million
Q4 2020 Feb 12, 2021	BUY	$25.27 - $54.9 $795,322 - $1.73 Million	31,473 New	31,473 $1.64 Million

338

88.3M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Parkwood LLC, based on Form 13F filings with the SEC.

Stay updated on Parkwood LLC with notifications on news.